stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) Shares outstanding
BioNTech SE Sponsored ADR's shares outstanding at the end of fiscal 2025 was $241.7M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $252.7M. Over the past ten years it has ranged from $9.0M (fiscal 2017) to $259.7M (fiscal 2021); the current reading is higher than 56% of that period. BioNTech SE Sponsored ADR ranks 31st of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $241.7M | 0.54% |
| FY2024 | $240.4M | (0.95%) |
| FY2023 | $242.7M | (2.84%) |
| FY2022 | $249.8M | (3.81%) |
| FY2021 | $259.7M | 4.50% |
| FY2020 | $248.5M | 17.51% |
| FY2019 | $211.5M | 10.90% |
| FY2018 | $190.7M | 2,019.00% |
| FY2017 | $9.0M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $252.7M | (0.23%) |
| Jun 2026 | $253.3M | 0.03% |
| Mar 2026 | $253.3M | 4.79% |
| Dec 2025 | $241.7M | 1.06% |
| 24 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ROIV Roivant Sciences Ltd. compare | $720.8M |
| GMAB Genmab A/S Sponsored ADR compare | $617.1M |
| EXEL Exelixis, Inc. compare | $255.8M |
| BNTX BioNTech SE Sponsored ADR | $252.7M |
| INSM Insmed, Inc. compare | $218.8M |
| INCY Incyte Corporation compare | $203.2M |
| BBIO BridgeBio Pharma, Inc. compare | $196.0M |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $138.0M |
| ASND Ascendis Pharma A/S compare | $68.3M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement